Wize Pharma, Inc. (WIZP) SEC Filing 8-K Material Event for the period ending Tuesday, February 16, 2021

Wize Pharma, Inc.

CIK: 1218683 Ticker: WIZP

View differences made from one to another to evaluate Wize Pharma, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Wize Pharma, Inc..


Assess how Wize Pharma, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Wize Pharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Wize Pharma, Inc. provided additional information to their SEC Filing as exhibits

Ticker: WIZP
CIK: 1218683
Form Type: 8-K Corporate News
Accession Number: 0001213900-21-009271
Submitted to the SEC: Tue Feb 16 2021 8:37:32 AM EST
Accepted by the SEC: Tue Feb 16 2021
Period: Tuesday, February 16, 2021
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: